185 related articles for article (PubMed ID: 15566571)
21. Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cells.
Tanaka T; Watanabe S; Takahashi M; Sato K; Saida Y; Baba J; Arita M; Sato M; Ohtsubo A; Shoji S; Nozaki K; Ichikawa K; Kondo R; Aoki N; Ohshima Y; Sakagami T; Abe T; Moro H; Koya T; Tanaka J; Kagamu H; Yoshizawa H; Kikuchi T
PLoS One; 2017; 12(8):e0183976. PubMed ID: 28854279
[TBL] [Abstract][Full Text] [Related]
22. Tumor-induced suppression of antitumor reactivity and depression of TCRzeta expression in tumor-draining lymph node lymphocytes: possible relationship to the Th2 pathway.
Fu EJ; Arca MJ; Hain JM; Krinock R; Rado J; Cameron MJ; Chang AE; Sondak VK
J Immunother; 1997 Mar; 20(2):111-22. PubMed ID: 9087383
[TBL] [Abstract][Full Text] [Related]
23. Adoptive immunotherapy mediated by anti-TCR/IL-2-activated tumour-draining lymph node cells.
Mitsuma S; Yoshizawa H; Ito K; Moriyama H; Wakabayashi M; Chou T; Arakawa M; Shu S
Immunology; 1994 Sep; 83(1):45-51. PubMed ID: 7821965
[TBL] [Abstract][Full Text] [Related]
24. Neoantigen-specific stem cell memory-like CD4
Brightman SE; Becker A; Thota RR; Naradikian MS; Chihab L; Zavala KS; Ramamoorthy Premlal AL; Griswold RQ; Dolina JS; Cohen EEW; Miller AM; Peters B; Schoenberger SP
Nat Immunol; 2023 Aug; 24(8):1345-1357. PubMed ID: 37400675
[TBL] [Abstract][Full Text] [Related]
25. Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model.
Ito F; Carr A; Svensson H; Yu J; Chang AE; Li Q
J Immunother; 2003; 26(3):222-33. PubMed ID: 12806276
[TBL] [Abstract][Full Text] [Related]
26. Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12.
Gollob JA; Schnipper CP; Orsini E; Murphy E; Daley JF; Lazo SB; Frank DA; Neuberg D; Ritz J
J Clin Invest; 1998 Aug; 102(3):561-75. PubMed ID: 9691093
[TBL] [Abstract][Full Text] [Related]
27. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
Bristol JA; Schlom J; Abrams SI
Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
29. Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rα
Kim SH; Cho E; Kim YI; Han C; Choi BK; Kwon BS
Nat Commun; 2021 Sep; 12(1):5314. PubMed ID: 34493727
[TBL] [Abstract][Full Text] [Related]
30. Autoreactive effector/memory CD4+ and CD8+ T cells infiltrating grafted and endogenous islets in diabetic NOD mice exhibit similar T cell receptor usage.
Diz R; Garland A; Vincent BG; Johnson MC; Spidale N; Wang B; Tisch R
PLoS One; 2012; 7(12):e52054. PubMed ID: 23251685
[TBL] [Abstract][Full Text] [Related]
31. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors.
Plautz GE; Mukai S; Cohen PA; Shu S
J Immunol; 2000 Oct; 165(7):3656-62. PubMed ID: 11034369
[TBL] [Abstract][Full Text] [Related]
32. Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/interleukin-2-activated tumor-draining lymph node cells.
Wahl WL; Sussman JJ; Shu S; Chang AE
J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):242-50. PubMed ID: 8061896
[TBL] [Abstract][Full Text] [Related]
33. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
[TBL] [Abstract][Full Text] [Related]
34. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
35. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
[TBL] [Abstract][Full Text] [Related]
36. Regulatory function for murine intraepithelial lymphocytes. Two subsets of CD3+, T cell receptor-1+ intraepithelial lymphocyte T cells abrogate oral tolerance.
Fujihashi K; Taguchi T; McGhee JR; Eldridge JH; Bruce MG; Green DR; Singh B; Kiyono H
J Immunol; 1990 Oct; 145(7):2010-9. PubMed ID: 1975820
[TBL] [Abstract][Full Text] [Related]
37. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.
Lutz-Nicoladoni C; Wallner S; Stoitzner P; Pircher M; Gruber T; Wolf AM; Gastl G; Penninger JM; Baier G; Wolf D
Immunol Cell Biol; 2012 Jan; 90(1):130-4. PubMed ID: 21383769
[TBL] [Abstract][Full Text] [Related]
38. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S
Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606
[TBL] [Abstract][Full Text] [Related]
39. A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy.
Alvarez-Fernández C; Escribà-Garcia L; Vidal S; Sierra J; Briones J
J Transl Med; 2016 Jul; 14(1):214. PubMed ID: 27435312
[TBL] [Abstract][Full Text] [Related]
40. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
